Samsung Biologics’ CMO orders exceed KRW 3 trillion this yr

Signs 5 contracts…cumulative annual order to be around KRW 3.5 trillion

Samsung Biologics

Samsung Biologics announced on the 28th that its contract manufacturing organization (CMO) orders this year will exceed KRW 3 trillion.

 

On the day, the company publicly announced that it signed 1 new and 4 expanded CMO deals.

 

Samsung Biologics signed a CMO deal worth KRW 588.8 billion with Asian pharmaceutical companies.

 

In addition, the CMO order amount increased by KRW 171.9 billion with the 4 expanded contracts, As a result, the company's cumulative annual CMO order amount has reached KRW 3.4867 trillion, surpassing KRW 3 trillion for the first time since its establishment.

 

The company explained, “Based on the solid trust we have built with our customers, large multinational pharmacuetical companies.

 

that have initially signed agreements with us have all expanded the contracted line of products or increased the production scale of previously contracted quantities, strengthening partnerships thereafter.” The company’s fourth plant, which began full operations in June, is the world's largest facility with a production capacity of 240,000 liters.

 

The plant has been continuously recording a high utilization rate due to the increase in large-scale orders from large multinational pharmacuetical companies.

 

Samsung Biologics is currently operating 4 biopharmaceutical manufacturing plants.

 

The company further strengthened its CMO capacity by starting its fourth factory 23 months after construction in October last year, which has the world's largest production capacity (240,000 liters) for a single plant.

 

Samsung Biologics has secured a total production capacity of 618,000 liters along with the existing 3 factories (Plant 1 30,000 liters, Plant 2 152,000 liters, Plant 3 180,000 liters).

 

In order to preemptively respond to market demand, Samsung Biologics began construction of a fifth plant with a 180,000 capacity last April with the goal of completion in April 2025.

 

When the fifth factory is completed, Samsung Biologics' total production capacity will be expanded to 784,000 liters.